Prostate Cancer

Brian F. Chapin, MD, assistant professor, Department of Urology, Division of Surgery, The University of Texas MD Anderson Cancer Center, discusses impact of active surveillance in the field of prostate cancer.

Susan F. Slovin, MD, PhD, a medical oncologist at Memorial Sloan Kettering Cancer Center, discusses the future of immunotherapy for patients with prostate cancer.

Christopher J. Kane, MD, professor of Surgery, chair, Department of Urology, UC San Diego Health, discusses the impact of genetic testing on patients with prostate cancer.

E. David Crawford, MD, professor of Radiation Oncology, University of Colorado School of Medicine, discusses ongoing trials regarding genetic testing for patients with prostate cancer.

As a wealth of research has shown in the past several years, therapies that target the androgen receptor pathway in patients with castration-resistant prostate cancer encounter complex mechanisms of resistance including the likelihood that more than 1 such signaling network is active in each individual.

Robert Dreicer, MD, highlights several emerging treatments for patients with metastatic castration-resistant prostate cancer.

Celestia Higano, MD, professor of Medicine and Urology, University of Washington, member of the Clinical Research Division at Fred Hutchinson Cancer Research Center, discusses results of docetaxel (Taxotere) versus hormone therapy in patients with metastatic hormone-sensitive prostate cancer.

The presence of androgen receptor splice variant-7 (AR-V7) mRNA in circulating tumor cells predicted poorer outcomes for men with castration-resistant prostate cancer assigned to novel hormonal therapies, according to results recently published in the Journal of Clinical Oncology.

James B. Yu, MD, associate professor, therapeutic oncology, director, Prostate and Genitourinary Cancer Radiotherapy Program, Yale Cancer Center, discusses current data in support of using moderate hypofractionation in prostate cancer.

The US Preventive Services Task Force may move away from its long-standing opposition to routine PSA screening for prostate cancer in some men.

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses potential immunotherapy agents for patients with prostate cancer.

Padmanee Sharma, MD, PhD, discusses the significance of the VISTA immune-checkpoint pathway in prostate cancer, and her proposed novel immunotherapy approach for patients with these tumors.

Celestia Higano, MD, discusses the early use of chemotherapy, the potential for PARP inhibitors, and the evolving role of radium-223 in prostate cancer.

Adam Dicker, MD, PhD, professor, chair, department of Radiation Oncology Sidney Kimmel Cancer Center, Thomas Jefferson University, discusses the impact of genetic testing for patients with prostate cancer.

Daniel A. Barocas, MD, discusses the benefits of active surveillance in patients with low-risk prostate cancer.

James B. Yu, MD, discusses results of a study on moderate hypofractionation in patients with prostate cancer, as well as recent data demonstrating how genomic testing can be helpful in postoperative treatment decision making.

E. David Crawford, MD, shares insight on incorporating ADT, specifically degarelix, into the prostate cancer landscape and why it remains to be a standard go-to approach for patients.

Robert Dreicer, MD, associate director for Clinical Research and deputy director of the University of Virginia Cancer Center, discusses abiraterone acetate (Zytiga) and enzalutamide (Xtandi) in metastatic castration-resistant prostate cancer (mCRPC).

Susan F. Slovin, MD, PhD, discusses the current state of immunotherapy in prostate cancer.

Susan F. Slovin, MD, PhD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the current role of immunotherapy in patients with advanced prostate cancer.

Wassim Abida, MD, PhD, medical oncologist, Developmental Therapeutics Center, Memorial Sloan Kettering Cancer Center, discusses genetic testing for patients with prostate cancer.

Paul G. Corn, MD, PhD, discusses recent advances in prostate cancer and the potential for immunotherapy and PARP inhibitors in the field.

Seungtaek L. Choi, MD, discussed the latest developments with radiation therapy in prostate cancer.

John C. Araujo, MD, PhD, assistant professor, Department of Genitourinary Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses emerging data with radium-223 dichloride (Xofigo) for the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC). Araujo shared this insight during the 2017 OncLive® State of the Science Summit on Genitourinary Cancers.

Leonard Gomella, MD, discusses the current state and critical next steps for optimizing genetic testing in prostate cancer.